Faron to Present at H.C. Wainwright

RNS Number : 3089K

Faron Pharmaceuticals Oy

04 January 2021

 

Faron Pharmaceuticals Oy

("Faron" or the "Company")

Faron to Present at H.C. Wainwright BioConnect

TURKU - FINLAND, January 4, 2021 - Faron Pharmaceuticals Ltd ( " Faron") (LON: FARN), the clinical stage biopharmaceutical company , today announced that Dr. Markku Jalkanen, Chief Executive Officer of Faron Pharmaceuticals, will present in a pre-recorded presentation at the virtual H.C. Wainwright BioConnect Conference that will be available on-demand starting Monday, January 11, 2021 at 6:00 a.m. ET.

An audio webcast of the presentations will be available in the "Investors" section on Faron's website at https://www.faron.com/investors  

ENDS

For more information please contact:

Stern Investor Relations, Inc.

Julie Seidel, Naina Zaman

Phone: +(1)212 362 1200

Email: [e-mail]  

Consilium Strategic Communications

Mary-Jane Elliott, David Daley, Lindsey Neville

Phone: [phone]

E-mail: [e-mail]

About Faron Pharmaceuticals Ltd

Faron (AIM: FARN, First North: FARON) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline based on the receptors involved in regulation of immune response in oncology and organ damage. Clevegen (bexmarilimab), its investigative precision immunotherapy, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development. Currently in phase I/II clinical development as a novel macrophage checkpoint immunotherapy for patients with untreatable solid tumours, Clevegen has potential as a single-agent therapy or in combination with other standard treatments including immune checkpoint molecules. Traumakine, the Company's pipeline candidate to prevent vascular leakage and organ failures is currently being tested in several Phase III studies around the world against COVID-19. Traumakine is intravenous IFN beta-1a, which is a strong anti-viral and anti-inflammatory agent. Faron is based in Turku, Finland. Further information is available at www.faron.com  

 

END

 

 

NRAKKDBNDBDDFBN